49,605 Shares in Xencor, Inc. (NASDAQ:XNCR) Bought by Y Intercept Hong Kong Ltd

Key Points

• Y Intercept Hong Kong Ltd has acquired 49,605 shares of Xencor, Inc. valued at approximately $528,000, representing 0.07% ownership of the company.
• Institutional investors such as RTW Investments LP and BVF Inc. IL have markedly increased their stakes in Xencor, with RTW boosting its holdings by 317.9% in the last quarter.
• Xencor reported a revenue of $32.73 million for the quarter, exceeding expectations, despite an EPS miss of ($0.66) against a consensus estimate of ($0.60).

Y Intercept Hong Kong Ltd purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 49,605 shares of the biopharmaceutical company's stock, valued at approximately $528,000. Y Intercept Hong Kong Ltd owned approximately 0.07% of Xencor at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of XNCR. CWM LLC grew its holdings in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. Principal Financial Group Inc. boosted its position in Xencor by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company's stock valued at $3,710,000 after buying an additional 8,581 shares during the period. New York State Teachers Retirement System boosted its position in Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock valued at $631,000 after buying an additional 1,200 shares during the period. Diversified Trust Co purchased a new stake in Xencor during the 1st quarter valued at $172,000. Finally, Exchange Traded Concepts LLC boosted its position in Xencor by 23.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock valued at $104,000 after buying an additional 1,896 shares during the period.

Xencor Price Performance

Xencor stock traded down $0.23 during mid-day trading on Thursday, reaching $8.51. 131,994 shares of the company's stock traded hands, compared to its average volume of 760,391. The company has a quick ratio of 5.89, a current ratio of 5.89 and a debt-to-equity ratio of 0.16. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24. The company has a market cap of $605.30 million, a price-to-earnings ratio of -2.76 and a beta of 0.85. The stock has a 50 day moving average of $8.66 and a two-hundred day moving average of $11.58.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The firm's revenue was up 104.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.11) earnings per share. Equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Activity at Xencor

In related news, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director directly owned 20,183 shares of the company's stock, valued at $186,087.26. This represents a 12.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard J. Ranieri sold 2,993 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,810 shares of company stock valued at $154,123 in the last quarter. Corporate insiders own 4.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on XNCR. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research report on Thursday, May 8th. Finally, William Blair began coverage on shares of Xencor in a research note on Monday, April 21st. They set an "outperform" rating for the company. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $28.00.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.